Estimating the changing burden of disease attributable to high systolic blood pressure in South Africa for 2000, 2006 and 2012.


Journal

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
ISSN: 2078-5135
Titre abrégé: S Afr Med J
Pays: South Africa
ID NLM: 0404520

Informations de publication

Date de publication:
30 09 2022
Historique:
received: 29 09 2022
entrez: 2 12 2022
pubmed: 3 12 2022
medline: 6 12 2022
Statut: epublish

Résumé

Ongoing quantification of trends in high blood pressure and the consequent disease impact are crucial for monitoring and decision-making. This is particularly relevant in South Africa (SA) where hypertension is well-established. To quantify the burden of disease related to high systolic blood pressure (SBP) in SA for 2000, 2006 and 2012, and describe age, sex and population group differences. Using a comparative risk assessment methodology, the disease burden attributable to raised SBP was estimated according to age, se, and population group for adults aged ≥25 years in SA in the years 2000, 2006 and 2012. We conducted a meta-regression on data from nine national surveys (N=124 350) to estimate the mean and standard deviation of SBP for the selected years (1998 - 2017). Population attributable fractions were calculated from the estimated SBP distribution and relative risk, corrected for regression dilution bias for selected health outcomes associated with a raised SBP, above a theoretical minimum of 110 - 115 mmHg. The attributable burden was calculated based on the estimated total number of deaths and disability-adjusted life years (DALYs). Mean SBP (mmHg) between 2000 and 2012 showed a slight increase for adults aged ≥25 years (127.3 - 128.3 for men; 124.5 - 125.2 for women), with a more noticeable increase in the prevalence of hypertension (31% - 39% in men; 34% - 40% in women). In both men and women, age-standardised rates (ASRs) for deaths and DALYs associated with raised SBP increased between 2000 and 2006 and then decreased in 2012. In 2000 and 2012, for men, the death ASR (339/100 000 v. 334/100 000) and DALYs (5 542/100 000 v. 5 423/100 000) were similar, whereas for women the death ASR decreased (318/100 000 v. 277/100 000) as did age-standardised DALYs (5 405/100 000 v. 4 778/100 000). In 2012, high SBP caused an estimated 62 314 deaths (95% uncertainty interval 62 519 - 63 608), accounting for 12.4% of all deaths. Stroke (haemorrhagic and ischaemic), hypertensive heart disease and ischaemic heart disease accounted for >80% of the disease burden attributable to raised SBP over the period. From 2000 to 2012, a stable mean SBP was found despite an increase in hypertension prevalence, ascribed to an improvement in the treatment of hypertension. Nevertheless, the high mortality burden attributable to high SBP underscores the need for improved care for hypertension and cardiovascular diseases, particularly stroke, to prevent morbidity and mortality.

Sections du résumé

BACKGROUND
Ongoing quantification of trends in high blood pressure and the consequent disease impact are crucial for monitoring and decision-making. This is particularly relevant in South Africa (SA) where hypertension is well-established.
OBJECTIVE
To quantify the burden of disease related to high systolic blood pressure (SBP) in SA for 2000, 2006 and 2012, and describe age, sex and population group differences.
METHODS
Using a comparative risk assessment methodology, the disease burden attributable to raised SBP was estimated according to age, se, and population group for adults aged ≥25 years in SA in the years 2000, 2006 and 2012. We conducted a meta-regression on data from nine national surveys (N=124 350) to estimate the mean and standard deviation of SBP for the selected years (1998 - 2017). Population attributable fractions were calculated from the estimated SBP distribution and relative risk, corrected for regression dilution bias for selected health outcomes associated with a raised SBP, above a theoretical minimum of 110 - 115 mmHg. The attributable burden was calculated based on the estimated total number of deaths and disability-adjusted life years (DALYs).
RESULTS
Mean SBP (mmHg) between 2000 and 2012 showed a slight increase for adults aged ≥25 years (127.3 - 128.3 for men; 124.5 - 125.2 for women), with a more noticeable increase in the prevalence of hypertension (31% - 39% in men; 34% - 40% in women). In both men and women, age-standardised rates (ASRs) for deaths and DALYs associated with raised SBP increased between 2000 and 2006 and then decreased in 2012. In 2000 and 2012, for men, the death ASR (339/100 000 v. 334/100 000) and DALYs (5 542/100 000 v. 5 423/100 000) were similar, whereas for women the death ASR decreased (318/100 000 v. 277/100 000) as did age-standardised DALYs (5 405/100 000 v. 4 778/100 000). In 2012, high SBP caused an estimated 62 314 deaths (95% uncertainty interval 62 519 - 63 608), accounting for 12.4% of all deaths. Stroke (haemorrhagic and ischaemic), hypertensive heart disease and ischaemic heart disease accounted for >80% of the disease burden attributable to raised SBP over the period.
CONCLUSION
From 2000 to 2012, a stable mean SBP was found despite an increase in hypertension prevalence, ascribed to an improvement in the treatment of hypertension. Nevertheless, the high mortality burden attributable to high SBP underscores the need for improved care for hypertension and cardiovascular diseases, particularly stroke, to prevent morbidity and mortality.

Identifiants

pubmed: 36458347
doi: 10.7196/SAMJ.2022.v112i8b.16542
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

571-582

Auteurs

B Nojilana (B)

Burden of Disease Research Unit, South African Medical Research Council, Cape Town, South Africa. beatrice.nojilana@mrc.ac.za.

N Peer (N)

Non-communicable Diseases Research Unit, South African Medical Research Council, Durban, South Africa 3 Department of Medicine, University of Cape Town, South Africa. beatrice.nojilana@mrc.ac.za.

N Abdelatif (N)

Biostatistics Research Unit, South African Medical Research Council, Cape Town South Africa. beatrice.nojilana@mrc.ac.za.

A Cois (A)

Burden of Disease Research Unit, South African Medical Research Council, Cape Town, South Africa; Division of Health Systems and Public Health, Department of Global Health, Stellenbosch University, South Africa . beatrice.nojilana@mrc.ac.za.

A E Schutte (AE)

School of Population Health, University of New South Wales, Australia; The George Institute for Global Health, Sydney, Australia; Hypertension in Africa Research Team, South African Medical Research Council Unit for Hypertension and Cardiovascular Disease, North West University, Potchefstroom, South Africa. beatrice.nojilana@mrc.ac.za.

D Labadarios (D)

Professor Emeritus, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa. beatrice.nojilana@mrc.ac.za.

E B Turuwa (EB)

Burden of Disease Research Unit, South African Medical Research Council, Cape Town, South Africa. beatrice.nojilana@mrc.ac.za.

R A Roomaney (RA)

Burden of Disease Research Unit, South African Medical Research Council, Cape Town, South Africa. rifqah.roomaney@mrc.ac.za.

O F Awotiwon (OF)

Burden of Disease Research Unit, South African Medical Research Council, Cape Town, South Africa. Oluwatoyin.Awotiwon@mrc.ac.za.

I Neethling (I)

Burden of Disease Research Unit, South African Medical Research Council, Cape Town, South Africa; Institute for Lifecourse Development, Faculty of Education, Health and Human Sciences, University of Greenwich, UK. Ian.Neethling@mrc.ac.za.

R A Roomaney (RA)

Institute for Lifecourse Development, Faculty of Education, Health and Human Sciences, University of Greenwich, UK. beatrice.nojilana@mrc.ac.za.

V Pillay-van Wyk (V)

Burden of Disease Research Unit, South African Medical Research Council, Cape Town, South Africa. beatrice.nojilana@mrc.ac.za.

D Bradshaw (D)

Burden of Disease Research Unit, South African Medical Research Council, Cape Town, South Africa; Department of Family Medicine and Public Health, University of Cape Town, South Africa . beatrice.nojilana@mrc.ac.za.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH